Whether you’re evaluating a new treatment, product, or technique, nothing speaks louder than clinical data. Every offering in our PCI portfolio represents a body of research spanning four decades. No matter what you need, our portfolio delivers the safety, efficacy, and performance you demand- backed by data you can trust.
The SYNTAX II Trial evaluated patients with three-vessel disease resulting in equivalent outcomes to CABG at 3-years. By utilizing contemporary PCI tools and techniques such as: physiological assessment, IVUS Guidance, current revascularization techniques, and contemporary technology, the SYNTAX II Trial produced CABG-like outcomes.
*The safety and effectiveness of the SYNERGY Stent has not been established with three-vessel disease or chronic total occlusions.
Properly preparing a vessel ensures proper stent placement and apposition and reduces the risk of long-term outcomes. Coronary calcium is a growing problem and is more common than you think. In the last two decades there has been a 31% increase of calcium prevalence and in the United States, over 30% of all patients treated for PCI present with calcium.
1. Cavusoglu E, et al. Cathet Cardivasc Intervent. 2004;62:485-498.
2. Moussa I, et al. Circulation. 1997;96(1):128-136
3. Mosseri M, et al. Cardiovasc Revasc Med. 2005;6:147-53.
The Importance of IVUS and Physiology-Guided Procedures
In a recent study IVUS use changed the procedure 74% of the time. Utilizing IVUS can help optimize your approach and lead to better outcomes. IVUS-guidance led to the use of larger stents or balloons, more post-dilation, additional stenting, or higher pressures in patients- resulting in lower rates of Stent Thrombosis (ST), Myocardial Infarction (MI) and Target Lesion Revascularization (TLR).1
The advancements in coronary physiology give you more options. Choose the measurement (FFR, DFR or Pd/Pa) that is best for your patient’s case.
Multiple studies support the use of FFR to identify ischemia-producing lesions and showed improved outcomes over angio-guided procedures alone. Mostly commonly used in clinical studies is an FFR cutoff of <- 0.80 to either defer or treat.
1. Maehara A. ADAPT-DES IVUS Substudy: Utility of IVUS in Delineating the Mechanism of and Preventing Stent Thrombosis. Cardiovascular Research Foundation/Columbia University Medical Center, NY.
The Bioabsorbable Polymer Difference
Permanent polymer stents are linked with a continuous accrual of events. Unlike permanent polymer DES technology, SYNERGY Stent’s Bioabsorbable Polymer is gone shortly after the drug is completely eluted. In studies of more than 35,000 patients, SYNERGY BP Stent provided outstanding safety and consistently low ST rates across various patient and lesion complexities.
Kang Network Meta-Analysis
SYNERGY BP Stent ranked #1 for the lowest relative risk of def/prob ST at 1-year.1
Lowest ST rate compared to newer generation DES (n-DES) despite use in patients with statistically more Class B2/C lesions, diabetes, prior PCI and 3VD.2
The SYNERGY BP Stent is the first DES indicated for use in High Bleeding Risk Patients. Based on the results of the EVOLVE Short DAPT Trial, SYNERGY BP Stent can be safely used in conjunction with shortened DAPT patients at high risk for bleeding.3
1. Kang S et al. J Am Coll Cardiol. Intv.doi:10.1016/j.jcin.2016.03.038.
2. Sarno G et al. Cathet. Cardiovasc. Intervent.. doi:10.1002/ccd.27030.
3. EVOLVE Short DAPT Subgroup Analyses. Presented by Robert Stoler, MD at ACC 2020.
Get exclusive product updates, training and educational opportunities, and more.